141 related articles for article (PubMed ID: 38175711)
21. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral
Yamamura K; Izumi D; Kandimalla R; Sonohara F; Baba Y; Yoshida N; Kodera Y; Baba H; Goel A
Clin Cancer Res; 2019 Oct; 25(20):6170-6179. PubMed ID: 31358543
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy for Thoracic Esophageal Squamous Cell Carcinoma.
Chan WWL; Lam KO; Kwong DLW
Methods Mol Biol; 2020; 2129():307-319. PubMed ID: 32056187
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
27. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
28. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
[No Abstract] [Full Text] [Related]
30. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
31. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
[TBL] [Abstract][Full Text] [Related]
32. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
Ann Surg Oncol; 2021 Dec; 28(13):8438-8447. PubMed ID: 34142294
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
37. Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.
Baba Y; Saeki H; Nakashima Y; Oki E; Shigaki H; Yoshida N; Watanabe M; Maehara Y; Baba H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27868285
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma.
Takahashi T; Kaneoka Y; Maeda A; Takayama Y; Seita K
Updates Surg; 2022 Apr; 74(2):675-683. PubMed ID: 34559400
[TBL] [Abstract][Full Text] [Related]
39. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
